Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer's Disease
Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company's Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer's disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer's Disease (AD).
Alzheimer's disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060. 1 It is a leading cause of disability and death. AD develops over many years, long before symptoms are evident, but the lack of accessible, minimally invasive diagnostics results in many patients remaining undiagnosed until the disease is well advanced, when few effective interventions remain.
The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test is an accurate, minimally invasive, accessible measurement of pTau 217 and β-Amyloid 1-42 concentrations in plasma as a proxy for the presence of β-Amyloid plaque pathology in the brain. It is intended for use in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. In a clinical study population of 499 patients, which closely mirrored the US demographics, and when applying a dual cut point, the test demonstrated a positive predicate value (PPV) of 92%, a negative predicate value (NPV) of 97% with only 20% patients who are uncertain to have amyloid pathology, thus requiring further testing.
The Lumipulse pTau 217/ β-Amyloid 1-42 Plasma Ratio test uses Fujirebio's fully automated LUMIPULSE ® G1200 instrument system, which is widely available in clinical laboratories throughout the U.S. The new ratio test complements the Lumipulse G β-Amyloid Ratio (1-42/1-40), authorized by the FDA for use in CSF in May 2022.
'The lack of effective, accessible and minimally invasive diagnostics for AD contributes to its late diagnosis and inadequate treatment,' says Monte Wiltse, President and CEO at Fujirebio Diagnostics, Inc. 'The Lumipulse G pTau 217/ β-Amyloid 1-42 Plasma Ratio test will go a long way to assist physicians and patients to obtain an AD diagnosis in early stages of the disease, when interventions are more effective. As part of our worldwide commitment to improve the diagnosis and treatment of AD, Fujirebio is developing additional assays, which will increase the availability of diagnostic tools and expand the foundation for early, more effective treatment.'
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.
Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/neuro.
About Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics, Inc., a wholly-owned subsidiary of Fujirebio Holdings, Inc., is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. The company pioneered and introduced the CA125 test, the first FDA-approved ovarian cancer biomarker, over 25 years ago. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at www.fujirebio.com.
Reference
1. (2025), 2025 Alzheimer's disease facts and figures. Alzheimer's Dement., 21: e70235. https://doi.org/10.1002/alz.70235
View source version on businesswire.com:https://www.businesswire.com/news/home/20250517132520/en/
CONTACT: MEDIA CONTACT:Chris Dague
Fujirebio Diagnostics, Inc.
Office: 484-395-5556
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA ASIA PACIFIC PENNSYLVANIA
INDUSTRY KEYWORD: GENETICS HEALTH NEUROLOGY MEDICAL DEVICES
SOURCE: FUJIREBIO
Copyright Business Wire 2025.
PUB: 05/17/2025 02:58 AM/DISC: 05/17/2025 02:57 AM
http://www.businesswire.com/news/home/20250517132520/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
39 minutes ago
- Chicago Tribune
FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff
WASHINGTON — The government's top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released Wednesday. The new memos from the Food and Drug Administration show how the agency's vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna. Both vaccines were approved by the FDA in May after months of analysis by rank-and-file FDA reviewers. But internal correspondence show Prasad disagreed with staffers who planned to approve the shots for everyone 12 and older, similar to previous COVID vaccines. The scientists had concluded the benefit from the vaccines and the risk of COVID-19 outweighed the risk of possible side effects, which are rare. Instead Prasad decided the shots should be limited to those who face special risks from the virus— seniors or children and adults with underlying medical issues. Prasad explained that the COVID vaccine benefits must be reconsidered in light of falling rates of death and hospitalization and the possibility for vaccine side effects. It's the latest in a series of vaccine restrictions imposed by officials working under Kennedy, who has long questioned the benefits of vaccines. 'Even rare vaccination related harms both known and unknown now have higher chance of outweighing potential benefits' Prasad wrote in a five-page memo explaining his decision. COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the Centers for Disease Control and Prevention. Most at risk for hospitalization are seniors and children under 2 — especially infants under 6 months. Top FDA leaders are typically not involved in the review of individual products. Officials like Prasad can overrule staffers, but such cases are rare and often controversial. News of the FDA documents was first reported by the New York Times. Prasad was hired to lead the FDA's vaccine center in May, after the previous director, Dr. Peter Marks, was forced to resign over disagreements with Kennedy. An academic researcher specializing in cancer therapies, Prasad came to prominence during the pandemic for criticizing public health measures, including the FDA's approval of COVID boosters for healthy adults and children. Since arriving at the agency he has worked with FDA Commissioner Mark Makary on new guidelines that will limit approvals of future COVID boosters to higher-risk Americans, mainly seniors and those with medical conditions like asthma and obesity. Those limits match the terms FDA recently approved for Novavax's shot, Nuvaxovid and Moderna's mNexspike. Novavax's vaccine is the only protein-based coronavirus vaccine available in the U.S. Moderna's vaccine is an updated, lower-dose version of its existing mRNA-based vaccine. The review team for the Novavax vaccine pointed to data from a study in 30,000 adults, concluding that 'the risk-benefit assessment for this vaccine technology remains favorable.' FDA staff reached a similar conclusion for the Moderna vaccine, deeming it similar in safety and effectiveness to the company's original shot. Last week, the FDA finalized new warning labeling about the risk of myocarditis, a rare form of heart inflammation, on shots from Moderna and Pfizer, the other maker of an mRNA-based shot for COVID. In his 'override memo,' reversing FDA staff's decision on the Moderna shot, Prasad pointed to the ongoing risk of myocarditis and questions about its frequency. The agency ordered Moderna to conduct further studies of the risk as a condition for the approving its updated shot. A spokesman for the administration said Prasad 'has raised serious concerns' about the issue. 'We will not ignore these risks and will ensure that the gold standard of science is used for any decisions,' said Andrew Nixon, in an emailed statement. Outside researchers have noted that cases of the heart condition tend to resolve quickly and are less severe than those associated with COVID infection itself, which can also cause myocarditis.
WIRED
43 minutes ago
- WIRED
Despite Protests, Elon Musk Secures Air Permit for xAI
Jul 2, 2025 7:41 PM xAI's gas turbines get official approval from Memphis, Tennessee, even as civil rights groups prepare to sue over alleged Clean Air Act violations. Photograph:A local health department in Memphis has granted Elon Musk's xAI data center an air permit to continue operating the gas turbines that power the company's Grok chatbot. The permit comes amid widespread community opposition and a looming lawsuit alleging the company violated the Clean Air Act. The Shelby County Health Department released its air permit for the xAI project Wednesday, after receiving hundreds of public comments. The news was first reported by the Daily Memphian. In June, the Memphis Chamber of Commerce announced that xAI had chosen a site in Memphis to build its new supercomputer. The company's website boasts that it was able to build the supercomputer, Colossus, in just 122 days. That speed was due in part to the mobile gas turbines the company quickly began installing at the campus, the site of a former manufacturing facility. Colossus allowed xAI to quickly catch up to rivals OpenAI, Google, and Anthropic in building cutting-edge artificial intelligence. It was built using 100,000 Nvidia H100 GPUs, making it likely the world's largest supercomputer. xAI's Memphis campus is located in a predominantly Black community known as Boxtown which has been historically burdened with industrial projects that cause pollution. Gas turbines like the ones xAI is using in Memphis can be a significant source of harmful emissions, like nitrogen oxides, which create smog. Memphis already has some of the highest child asthma rates in Tennessee. Since xAI began running its turbines, residents have repeatedly met and rallied against the project. 'My neighbors and I are forced to breathe the pollution this company pumps into our air every day. We smell it. We inhale it. This isn't just an environmental issue — it's a public health emergency,' wrote State Rep. Justin Pearson, who grew up near Boxtown, in an MSNBC op-ed last week. Under the Clean Air Act, 'major' sources of emissions—like a cluster of gas turbines—need a permit, known as a Prevention of Significant Deterioration (PSD) permit. However, Shelby County Health Department officials told local reporters in August that this wasn't necessary for xAI since its turbines weren't designed to be permanent. Amid mounting local opposition, xAI finally applied for a permit with the Shelby County Health Department in January, months after it first began running the turbines. Last month, the NAACP and the Southern Environmental Law Center (SELC) announced that they intended to sue xAI for violating the Clean Air Act. 'xAI's decision to install and operate dozens of polluting gas turbines without any permits or public oversight is a clear violation of the Clean Air Act,' said senior SELC attorney Patrick Anderson in a press release. 'Over the last year, these turbines have pumped out pollution that threatens the health of Memphis families. This notice paves the way for a lawsuit that can hold xAI accountable for its unlawful refusal to get permits for its gas turbines.' The new permit from the health department allows the company to operate 15 turbines on the site until 2027. In June, Memphis mayor Paul Young wrote an op-ed in the Tennessee Commercial Appeal that noted xAI was currently operating 21 turbines. SELC says that aerial footage it took in April, however, showed as many as 35 turbines operating at the site. xAI did not immediately respond to WIRED's request for comment, including questions about how many turbines it is currently operating at the facility. Shelby County did not immediately respond to a request for comment. In May, Sharon Wilson, a certified optical gas imaging thermographer, traveled to Memphis to film emissions from the site with a special optical gas imaging camera that records usually-invisible emissions. Wilson tracks leaks from facilities in the Permian Basin, one of the world's most prolific oil and gas-producing regions, in Texas. She alleged to WIRED that what she saw in Memphis was one of the densest clouds of emissions she'd ever seen. 'I expected to see the typical power plant type of pollution that I see,' she says. 'What I saw was way worse than what I expected.' This is a developing story. Please check back for updates .
Fast Company
44 minutes ago
- Fast Company
Critical minerals are in the U.S., not in far-off mines
The clean energy transition is accelerating—but it's running into a critical roadblock: the mineral supply chain. Lithium, cobalt, and other critical minerals power everything from electric vehicles to grid-scale batteries. But the world cannot mine these minerals fast enough to keep up. By 2040, global demand for lithium alone is expected to surge more than 700%. Yet traditional mining remains slow, polluting, and geopolitically risky. Industry leaders and policymakers agree: We can't build a sustainable tomorrow on an unsustainable supply chain. But there's a smarter solution—and it's already flowing beneath us. The minerals hidden in our water Lithium and other critical minerals are already present in surprising abundance—not only in traditional hard rock or salar basins, but in often-overlooked water sources like geothermal brines, industrial effluents, and oilfield produced water. For years, these streams were dismissed as too complex or costly to process. But that's beginning to change. Advancements in direct lithium extraction (DLE) are now making it possible to recover lithium from these unconventional sources—cleanly, efficiently, and at scale. By isolating lithium directly from water without relying on evaporation ponds or invasive mining operations, DLE opens access to vast untapped U.S. domestic reserves. While the potential is immense, DLE remains an emerging technology—one that only a few companies globally are starting to prove at commercially viable levels of recovery, purity, and sustainability. DLE technologies that balance performance, sustainability, and cost are likely to define the next generation of critical mineral production. Among the most promising approaches are integrated, modular systems that combine extraction, concentration, and conversion processes into a single platform. Clayton Valley in Nevada and regions like the Smackover Formation in Arkansas, Louisiana, and Texas, and the Marcellus Shale Formations in Pennsylvania, West Virginia, and New York, are emerging as the proving grounds for this next generation of lithium production. Here, innovative DLE platforms are being piloted in real-world conditions and tested for adaptability to diverse brines and scalability for industrial deployment. As regulatory support grows and urgency around domestic critical minerals intensifies, the outcomes from these early deployments are likely to shape the future blueprint for lithium extraction. Faster, cleaner, smarter Compared to conventional methods, DLE slashes production timelines from months—or even years—to just hours or days. It eliminates the need for expansive land use and significantly reduces the environmental footprint. As global demand for lithium surges, DLE represents more than a technical advancement—it's a radical shift toward cleaner, faster, and smarter mineral production. DLE also delivers powerful cost advantages over traditional hard rock mining and refining. Its modular, compact design requires far less capital investment, bypassing the need for open-pit mines and evaporation ponds. Operating costs are lower thanks to higher lithium recovery rates—often 60–90% versus 30–50%—and energy-efficient processes that use fewer chemicals. Faster deployment means quicker returns, and it's a lighter environmental footprint that streamlines permitting and regulatory approval. Combined, these benefits make DLE a breakthrough solution for the next generation of lithium production. Resilient supply chains start at home As geopolitical tensions strain access to global mineral reserves, the urgency for domestic solutions has never been greater. DLE offers the U.S. and other hard-rock-constrained nations a pathway to build resilient, local supply chains. This approach opens the door to new jobs and economic activity in otherwise overlooked geographies. U.S. policy is beginning to catch up. The federal government has designated critical mineral security a national imperative. Programs like the Department of Energy's MINER initiative are catalyzing research into greener, more efficient extraction methods. Still, government support alone isn't enough. It's time for the private sector to lead. The call to lead The minerals needed to power the future aren't buried in far-off mines in South America and Australia. They're right here, already flowing beneath us. Utilities, oilfield operators, and technology innovators already manage the infrastructure, data, and water resources that can power this next frontier. By reimagining wastewater not as a burden but as a resource, we can unlock new revenue streams. In doing so, we also help build resilient domestic supply chains and strengthen national energy security, reducing dependence on foreign lithium sources and securing the materials critical for the clean energy transition. It's time to stop digging deeper and start thinking smarter. Water isn't just a resource. It's a solution. For those bold enough to lead, it's the future.
